Biohaven BHVN
NYSE BHVN
$15.66 -0.20 (-1.26%)
As of: Sep 4, 2026 · 1:40 PM EDT

Biohaven (BHVN) Income towards Parent Company (2021 - 2026)

Biohaven (BHVN) posted Income towards Parent Company of -$130.5 million for Q1 2026, up 10.32% sequentially from -$145.6 million in Q4 2025, and up 41.12% YoY from -$92.5 million in Q1 2025.

Analysis

Biohaven (BHVN) Income towards Parent Company (2021 - 2026) Analysis & Trends

Biohaven has reported Income towards Parent Company for 6 years, with the latest figure at -$130.5 million in Q1 2026.

  • Quarterly Income towards Parent Company rose 41.12% year-over-year to -$130.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$647.7 million (up 27.11% YoY) and the FY2025 annual result came in at -$738.8 million, up 12.71% from the prior year.
  • Income towards Parent Company advanced to -$130.5 million in Q1 2026 per BHVN's latest filing, from -$145.6 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at -$68.9 million in Q3 2022 and troughed at -$319.8 million in Q2 2024.
  • A 5-year average of -$158.5 million and a median of -$160.3 million in 2024 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2022 and 2023: Income towards Parent Company slumped 287.59% in 2022, then surged 55.56% in 2023.
  • Over 5 years, Income towards Parent Company stood at -$201.1 million in 2022, then grew by 28.02% to -$144.8 million in 2023, then slipped by 29.07% to -$186.8 million in 2024, then increased by 22.1% to -$145.6 million in 2025, then increased by 10.32% to -$130.5 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$130.5 million, -$145.6 million, and -$173.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn -
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn -
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn
10 Biohaven 2.35 Bn 2.09 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -137.31 Mn
Mar 31, 2026 -130.53 Mn
Dec 31, 2025 -145.56 Mn
Sep 30, 2025 -173.44 Mn
Jun 30, 2025 -198.15 Mn
Mar 31, 2025 -221.68 Mn
Dec 31, 2024 -186.84 Mn
Sep 30, 2024 -160.30 Mn
Jun 30, 2024 -319.77 Mn
Mar 31, 2024 -179.50 Mn
Dec 31, 2023 -144.76 Mn
Sep 30, 2023 -102.57 Mn
Jun 30, 2023 -90.35 Mn
Mar 31, 2023 -70.49 Mn
Dec 31, 2022 -201.11 Mn
Sep 30, 2022 -68.85 Mn
Jun 30, 2022 -203.29 Mn
Mar 31, 2022 -97.03 Mn
Dec 31, 2021 -51.89 Mn
Sep 30, 2021 -54.37 Mn